Gauri A Patwardhan
Overview
Explore the profile of Gauri A Patwardhan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patwardhan G, Marczyk M, Wali V, Stern D, Pusztai L, Hatzis C
NPJ Breast Cancer
. 2021 May;
7(1):60.
PMID: 34040000
The effect of scheduling of targeted therapy combinations on drug resistance is underexplored in triple-negative breast cancer (TNBC). TNBC constitutes heterogeneous cancer cell populations the composition of which can change...
2.
Marczyk M, Patwardhan G, Zhao J, Qu R, Li X, Wali V, et al.
Cancers (Basel)
. 2020 Sep;
12(9).
PMID: 32911681
Cancer cells employ various defense mechanisms against drug-induced cell death. Investigating multi-omics landscapes of cancer cells before and after treatment can reveal resistance mechanisms and inform new therapeutic strategies. We...
3.
Wali V, Patwardhan G, Pelekanou V, Karn T, Cao J, Ocana A, et al.
Sci Rep
. 2019 Oct;
9(1):14934.
PMID: 31624295
The goal of this study was to identify a novel target for antibody-drug conjugate (ADC) development in triple negative breast cancer (TNBC), which has limited treatment options, using gene expression...
4.
Perez-Pena J, Alcaraz-Sanabria A, Nieto-Jimenez C, Paez R, Corrales-Sanchez V, Serrano-Oviedo L, et al.
Oncotarget
. 2017 Apr;
8(13):21733-21740.
PMID: 28423514
Luminal breast tumors have been classified into A and B subgroups, with the luminal A being associated with a more favorable clinical outcome. Unfortunately, luminal A tumors do not have...
5.
Wali V, Langdon C, Held M, Platt J, Patwardhan G, Safonov A, et al.
Cancer Res
. 2016 Nov;
77(2):566-578.
PMID: 27872098
Triple-negative breast cancer (TNBC) remains an aggressive disease without effective targeted therapies. In this study, we addressed this challenge by testing 128 FDA-approved or investigational drugs as either single agents...
6.
Chang K, Anishkin A, Patwardhan G, Beverly L, Siskind L, Colombini M
Biochim Biophys Acta
. 2015 Jul;
1848(10 Pt A):2374-84.
PMID: 26215742
Ceramide is a bioactive sphingolipid involved in mitochondrial-mediated apoptosis. Our data suggest that ceramides directly regulate a key initiation step in apoptosis: mitochondrial outer membrane permeabilization (MOMP). MOMP allows release...
7.
Patwardhan G, Beverly L, Siskind L
J Bioenerg Biomembr
. 2015 Jan;
48(2):153-68.
PMID: 25620271
The sphingolipid family of lipids modulate several cellular processes, including proliferation, cell cycle regulation, inflammatory signaling pathways, and cell death. Several members of the sphingolipid pathway have opposing functions and...
8.
Patwardhan G, Hosain S, Liu D, Khiste S, Zhao Y, Bielawski J, et al.
Biochim Biophys Acta
. 2014 Sep;
1841(11):1571-80.
PMID: 25195822
Mutants of tumor suppressor p53 not only lose the activity in genome stabilizing and in tumor suppression, but also exhibit oncogenic function in cancer cells. Most efforts in restoring p53...
9.
Liu Y, Patwardhan G, Xie P, Gu X, Giuliano A, Cabot M
Int J Oncol
. 2011 May;
39(2):425-31.
PMID: 21617856
Drug resistance causes treatment failure in approximately 50% of breast cancer patients with chemotherapy. Overexpression of glucosylceramide synthase (GCS) confers drug resistance in cancer cells, and suppression of GCS sensitizes...
10.
Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells
Liu Y, Patwardhan G, Bhinge K, Gupta V, Gu X, Jazwinski S
Cancer Res
. 2011 Feb;
71(6):2276-85.
PMID: 21278235
Tumor suppressor p53 plays an essential role in protecting cells from malignant transformation by inducing cell-cycle arrest and apoptosis. Mutant p53 that is detected in more than 50% of cases...